[Alzheimer's disease - system prepardeness in the context of new developments].
The possible authorisation of new monoclonal antibody therapies for Alzheimer's disease poses challenges for healthcare systems worldwide. In this paper, the Swiss Memory Clinics association (SMC) analyses the available resources and identifies potential health care shortages. Overcoming potential bottlenecks is a challenge that requires action at various levels. However, our analysis also shows that we are well positioned in Switzerland to integrate new developments into existing care structures.
Authors
- Ansgar Felbecker
- Andreas U. Monsch (ORCID: https://orcid.org/0000-0003-1692-1560)
- Karl‐Olof Lövblad (ORCID: https://orcid.org/0000-0003-2768-9779)
- Markus Bürge (ORCID: https://orcid.org/0000-0003-0225-3979)
- Julius Popp (ORCID: https://orcid.org/0000-0002-0068-0312)
- Tatjana Meyer-Heim
- Rafael Meyer (ORCID: https://orcid.org/0000-0002-7668-9794)
- Anton Gietl (ORCID: https://orcid.org/0000-0001-8604-962X)
- Gilles Allali (ORCID: https://orcid.org/0000-0002-4455-6719)
- Marc Sollberger (ORCID: https://orcid.org/0000-0001-8863-3731)
- Aurélien Lathuilière (ORCID: https://orcid.org/0000-0002-5191-5214)
- Olivier Rouaud (ORCID: https://orcid.org/0000-0001-9767-8421)
- Hans H. Jung
- Stefanie Becker (ORCID: https://orcid.org/0000-0001-8503-6368)
- Giovanni B. Frisoni (ORCID: https://orcid.org/0000-0001-7075-7082)
- Nadège Barro-Belaygues
- Dan Georgescu
- Kathrin Lindheimer
Institutions
- Centre Hospitalier Universitaire Vaudois (CH)
- Federal Agency for Food Chain Safety (BE)
- Felix Platter-Hospital (CH)
- Schweizerischen Neurologischen Gesellschaft (CH)
- The Memory Clinic (US)
Publication Details
- Journal
- PubMed
- Published
- 2024-12-01
- DOI
- https://doi.org/10.23785/praxis.2024.11.002
- Citations
- 1
- Primary Topic
- Nutrition, Genetics, and Disease
- Type
- article